Disclosures for "Small Molecule Modulators of Metabolic Dysfunction as a Therapeutic Strategy For ALS")
-
Daniel Kaganovich has nothing to disclose.
-
Dr. Thomson has stock in Amylyx. Dr. Thomson has received intellectual property interests from a discovery or technology relating to health care.